RARE
Ultragenyx Pharmaceutical Inc.
There isn't enough reported data to score RARE yet.
RARE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
RARE's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
RARE PE Valuation
RARE has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 9.8x next year's earnings.
RARE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect RARE to return to profit, with revenue growing. However, they disagree widely on these estimates.
RARE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.67 | — |
| Q3 2026 | -$5.18 | +$0.71 |
| Q2 2026 | -$5.83 | -$0.35 |
| Q1 2026 | -$6.10 | -$0.27 |
| Q4 2025 | -$5.83 | +$0.46 |
| Q3 2025 | -$5.89 | +$0.50 |
| Q2 2025 | -$5.48 | +$1.74 |
| Q1 2025 | -$5.83 | +$2.12 |
| Q4 2024 | -$6.29 | +$1.96 |
RARE is still losing money, but less than at its worst: $5.18 per share over the past year, against $10.26 at its worst in early 2023.
RARE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $173M | +8.2% |
| Q2 2026 | $214M | +29% |
| Q1 2026 | $136M | -2.4% |
| Q4 2025 | $207.3M | +26% |
| Q3 2025 | $159.9M | +15% |
| Q2 2025 | $166.5M | +13% |
| Q1 2025 | $139.3M | +28% |
| Q4 2024 | $164.9M | +29% |
RARE's revenue is growing: $173M last quarter, up 8.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -64% | +43 points |
| Q2 2026 | -35% | +30 points |
| Q1 2026 | -124% | -22 points |
| Q4 2025 | -55% | +20 points |
| Q3 2025 | -107% | -12 points |
| Q2 2025 | -65% | +14 points |
| Q1 2025 | -103% | +49 points |
| Q4 2024 | -74% | +22 points |
RARE's operating margin was −64% last quarter, up 43 points from the same quarter a year ago.
RARE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$45M | +$47.7M |
| Q2 2026 | -$98M | +$12.7M |
| Q1 2026 | -$198M | -$30.2M |
| Q4 2025 | -$100.8M | -$20.6M |
| Q3 2025 | -$92.7M | -$24.1M |
| Q2 2025 | -$110.7M | -$31.8M |
| Q1 2025 | -$167.8M | +$26.1M |
| Q4 2024 | -$80.2M | +$5.3M |
RARE has burned cash in almost every quarter: −$442M over the past year, against −$451M the year before.
RARE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +200K shares |
| 1 year | +2.3% | +2.3M shares |
| 3 years | +42% | +30.4M shares |
| 5 years | +50% | +34.2M shares |
| Available history | +80% | +45.5M shares |
RARE has 102M diluted shares, up 2.3% from a year ago.
RARE Net Leverage
RARE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
RARE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.0 | Neutral |
| Stochastic | 20.3 | Neutral |
RARE's weekly RSI is 39 (neutral) and its Stochastic is 20 (neutral).
RARE PE vs Healthcare Sector
RARE has no meaningful PE right now: it lost money over the past year.
RARE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $15.4 | 5.6% above |
| 20 week MA | $21.0 | 22% below |
| 50 week MA | $23.4 | 31% below |
| 100 week MA | $29.5 | 45% below |
| 200 week MA | $37.2 | 56% below |
RARE has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 56% below its 200-week average.
RARE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $43.4 | $172.9 | +298% |
| 2021 | $172.9 | $84.7 | -51% |
| 2022 | $84.7 | $43.5 | -49% |
| 2023 | $43.5 | $47.8 | +9.9% |
| 2024 | $47.8 | $43.4 | -9.2% |
| 2025 | $43.4 | $34.2 | -21% |
| 2026 YTD | $34.2 | $16.3 | -52% |
RARE's yearly returns have swung widely, from +298% in 2020 to −51% in 2021. It's down 52% so far in 2026.